On May 28, 2026, the scientific and practical conference “EBMT Review – 2026”, organized by the Ukrainian Association of Pediatric Oncology/Hematology, will take place online. The event will bring together Ukrainian specialists in pediatric oncology and hematology to discuss modern international approaches to treatment and bone marrow transplantation.
The conference is dedicated to reviewing key topics and clinical solutions presented at the Annual Meeting of the EBMT 2026 — one of the world’s leading events in the field of hematopoietic stem cell transplantation and oncohematology. This year’s focus includes treatment of relapsed and refractory leukemias and lymphomas, modern strategies for managing post-transplant complications, immunotherapy and targeted therapy, as well as vaccination and long-term follow-up after HSCT.
Empirica Medical Company supports professional initiatives aimed at advancing evidence-based medicine and implementing innovative technologies into clinical practice. As part of the conference scientific program, the company will contribute with an international expert presentation dedicated to modern approaches to HLA typing.
The speaker representing Empirica Medical Company will be Dr. Thomas R. Turner — a leading expert in immunogenetics, Lead Immunogenetics Scientist at Anthony Nolan Research Institute and Honorary Research Fellow at UCL Cancer Institute.
Presentation topic:
“Immunogenetics of Hematopoietic Cell Transplantation”
During the presentation, the experience of applying long-read sequencing technologies by PacBio for HLA typing at the Anthony Nolan centre will be presented, where these technologies have been used in the United Kingdom since 2015. The presentation will cover modern approaches to the immunogenetic support of hematopoietic cell transplantation and the role of high-precision genetic analysis in improving treatment outcomes.
Participation in “EBMT Review – 2026” continues Empirica Medical Company’s commitment to supporting the professional medical community in Ukraine. International knowledge exchange, access to innovative technologies, and interdisciplinary dialogue contribute to the advancement of modern oncohematology and improved patient outcomes.
